



Date: 26th January 2012

Dr. Eric Abadie
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

Subject: Withdrawal of Pioglitazone Teva Generics, (pioglitazone), 15 mg, 30 mg and 45 mg tablets - EMEA/H/C/002448

Dear Dr. Eric Abadie,


I would like to inform you that, at this point of time, TEVA Generics B.V. has taken the decision to withdraw the application for Marketing Authorisation of Pioglitazone Teva Generics, (pioglitazone) , 15 mg, 30 mg and 45 mg tablets , which was intended to be used for the treatment of type 2 diabetes mellitus.

This withdrawal is based on the Company's marketing strategy.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

Yours sincerely,



Principal Regulatory Affairs Officer

Teva Generics B.V.

Computerweg 10, P.O. Box 43028, 3540 AA UTRECHT - The Netherlands
Phone: +31(0)346 290 250 – Fax: +31(0)346 290 299

Chamber of Commerce Utrecht 30099369, VAT NO 800 535 558 B01
Bank: Fortis (Nederland) N.V. Account NO. 24.06.53.602, IBAN: NL63FTSB0240653602, SWIFT: FTB2NL2R